Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP-P: Truvada PK in Pregnancy
NCT03834909Phase 1Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Apr 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Plasma Tenofovir Concentration at 36 weeks, Plasma Emtricitabine Concentration at 36 weeks and 2 more. Planned start Apr 2022; status: withdrawn.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03834909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834909.